Luminex Corporation Hosts Seventh Annual Planet xMAP Europe

Two-Day Multiplexing Technology Symposium Brings Together Leading Scientists to Explore New Developments in Clinical Diagnostics and Life Science Research

• Press Release
• Source: Luminex Corporation
• On 10:00 am EDT, Tuesday September 29, 2009

OOSTERHOUT, The Netherlands--(BUSINESS WIRE)--Luminex Corporation (NASDAQ: LMNX - News), the worldwide leader in multiplexed solutions, today announced that it will host Planet xMAP Europe 2009, its annual European multiplexing technology symposium, October 7-8, 2009, at Beurs van Berlage in Amsterdam. The program for Planet xMAP Europe 2009 includes workshops, presentations, discussion groups, scientific posters and networking events featuring scientists and researchers from around the world who are performing groundbreaking work in clinical diagnostics and life science research using Luminex’s xMAP® multiplexing technology platform.

“This event is a prime opportunity for researchers and scientists to assemble and share their knowledge on the innovative ways in which they are applying Luminex’s xMAP technology in their respective fields,” said Paul C. Ladestein, Senior Director of European Operations for Luminex. “We are welcoming a strong group of leaders across a number of disciplines whose exchanges in expertise are sure to benefit all involved.”

Related Quotes

Symbol	Price	Change
LMNX	13.89	-0.07

{"s" : "lmnx","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Planet xMAP Europe 2009 will feature two days of presentations and with six focused session options.

Day One of Planet xMAP Europe 2009, Wednesday, 7 October, will focus on Pathogen Detection, Immunology-Monitoring and HLA-Human Genetics.

The morning session will include the following presentations:

• Prof. Maurizio Ferrari, Hospital San Raffaelle—“Present and Future of Diagnostic Testing”
• Dr. Ray Borrow, Head of Vaccine Evaluation Unit Health Protection Agency North West, Manchester Laboratory, Manchester Royal Infirmary—“Microbial Antibody Testing-The Power of Multiplexing”
• Dr. Jutta Bachmann, Bachmann Consulting—“The Potential of Multiplex Diagnostics”
• Patrick Balthrop, CEO of Luminex Corporation—“Luminex Update: Next Generation of Multiplexing”

The afternoon sessions will feature three separate tracks focused on, Pathogen Detection, Immunology-Monitoring, and HLA- Human Genetics.

Day Two of Planet xMAP Europe 2009, Thursday, 8 October, will focus on Proteomics, Gene Expression and Newborn Screening

The morning session will feature the following presentations:

• Prof. Mathias Ulhen, KTH Biotechnology—“A Human Protein Atlas for profiling cells, tissues and organs”
• PharmD Anne-Sophie Chrétien, Laboratoire d’Anatomie Pathologique, Nancy Université, Centre Alexis Vautrin—“BIO-PLEX® Phosphoprotein Array Assay for Characterization of her downstream signaling functionality as Clinical Response Predictive Marker to Targeted Therapy in Breast Carcinoma, HNSCC and Colorectal Cancer”
• Prof. Mark Achtman, Environmental Research Institute, University College Cork—“A Multiplex Luminex Assay for Genotyping SNPs in gyrA, gyrB and parE of Salmonella Enterica Serovar Typhi that cause lessened Susceptibility to Fluoroquinolones”

The afternoon sessions will include discussions on Newborn Screening, Proteomics and Gene Expression.

Acquiring knowledge and sharing ideas and expertise is what Planet xMAP Europe 2009 is all about. Scientists and researchers who would like to share their xMAP experiences are welcome to submit an abstract for a poster presentation. Please send any submissions by email to François Topin at ftopin@luminexcorp.com.

For detailed information regarding the Planet xMAP Europe 2009 symposium and agenda or to register online, please visit http://www.planetxmap.com.

Luminex will host its annual Planet xMAP USA 2010 on May 12-14, 2010, at the Hilton Baltimore in Baltimore, MD. For more information or to submit an abstract, please visit www.luminexcorp.com/planetxmap.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained at www.luminexcorp.com.

Luminex Corporation
Corporate:
Harriss T. Currie, 512-219-8020
Vice President, Finance and Chief Financial Officer
hcurrie@luminexcorp.com
or
Investor Relations:
Mimi Torrington, 512-219-8020
Director of Investor Relations
mtorrington@luminexcorp.com
or
Media:
Nicole L. Cottrill, 615-327-7999
ncottrill@seigenthaler.com